TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.

doi:10.1038/s41408-023-00821-x

Article

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.

Blood cancer journal - 11 Apr 2023

Shah Mithun Vinod, Tran Elizabeth Ngoc Hoa, Shah Syed, Chhetri Rakchha, Baranwal Anmol, Ladon Dariusz, Shultz Carl, Al-Kali Aref, Brown Anna L, Chen Dong, Scott Hamish S, Greipp Patricia, Thomas Daniel, Alkhateeb Hassan B, Singhal Deepak, Gangat Naseema, Kumar Sharad, Patnaik Mrinal M, Hahn Christopher N, Kok Chung Hoow, Tefferi Ayalew, Hiwase Devendra K

Abstract excerpt

Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International Consensus Classification (ICC) and the World Health Organization (WHO) recommended major change pertaining to TP53-mutated (TP53mut) MN. However, these assertions have not been specifically examined in therapy-related myeloid neoplasm (t-MN), a subset enriched with TP53mut. We analyzed 488 t-MN patients for TP53mut. At least one...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.

Abstract excerpt

Topics

Related research